Clinical Trials Sponsored by Boehringer Ingelheim laboratory

Total 2524 results

Boehringer Ingelheim

Completed

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

Thromboembolism | Arthroplasty, Replacement

Austria, France, Germany, Italy, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
Boehringer Ingelheim

Completed

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Boehringer Ingelheim

Completed

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Ovarian Neoplasms

Belgium, France, Slovakia, Spain, Sweden
Boehringer Ingelheim

Completed

Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis

Liver Cirrhosis | Hepatitis C

Germany
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment

Hepatitis C

Germany
Boehringer Ingelheim

Completed

Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female Volunteers

HIV Infections

Germany
Boehringer Ingelheim

Completed

Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir

Healthy

Germany
Boehringer Ingelheim

Completed

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Breast Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
Boehringer Ingelheim

Completed

The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage

Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Healthy

Belgium
Boehringer Ingelheim

Completed

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Withdrawn

Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin

Healthy

Germany
Boehringer Ingelheim

Completed

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Healthy

Russian Federation
Boehringer Ingelheim

Completed

Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life

Arthritis, Rheumatoid | Osteoarthritis

Russian Federation, Czech Republic, Croatia, Estonia, Slovakia
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

Safety and PK Study of BIBF 1120 in Japanese Patients With IPF

Idiopathic Pulmonary Fibrosis

Japan
Boehringer Ingelheim

Completed

Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120

Neoplasms

France, Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin

Healthy

Germany
Boehringer Ingelheim

Completed

4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler

Pulmonary Disease, Chronic Obstructive

Australia, New Zealand, United Kingdom
Boehringer Ingelheim

Completed

Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) Patients

Parkinson Disease

China
Boehringer Ingelheim

Completed

Observational Study of Meloxicam in Any Labeled Indication

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Hypertension
Boehringer Ingelheim

Terminated

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Healthy
Boehringer Ingelheim

Completed

Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Healthy

3

Subscribe